Paclitaxel
"Paclitaxel" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.
Descriptor ID |
D017239
|
MeSH Number(s) |
D02.455.426.392.368.242.888.777 D02.455.849.291.850.777
|
Concept/Terms |
Anzatax- Anzatax
- Bull Brand of Paclitaxel
Taxol- Taxol
- Taxol A
- Bristol-Myers Squibb Brand of Paclitaxel
- Bris Taxol
- Bristol-Myers Brand of Paclitaxel
Praxel- Praxel
- Lemery Brand of Paclitaxel
Onxol- Onxol
- Ivax Brand of Paclitaxel
|
Below are MeSH descriptors whose meaning is more general than "Paclitaxel".
Below are MeSH descriptors whose meaning is more specific than "Paclitaxel".
This graph shows the total number of publications written about "Paclitaxel" by people in this website by year, and whether "Paclitaxel" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1990 | 0 | 1 | 1 | 1995 | 2 | 0 | 2 | 1996 | 1 | 1 | 2 | 1997 | 3 | 2 | 5 | 1998 | 0 | 2 | 2 | 1999 | 1 | 1 | 2 | 2000 | 2 | 3 | 5 | 2001 | 1 | 3 | 4 | 2002 | 0 | 1 | 1 | 2003 | 0 | 5 | 5 | 2004 | 2 | 1 | 3 | 2005 | 0 | 3 | 3 | 2006 | 1 | 3 | 4 | 2007 | 1 | 2 | 3 | 2008 | 1 | 4 | 5 | 2009 | 0 | 3 | 3 | 2010 | 0 | 1 | 1 | 2011 | 0 | 2 | 2 | 2012 | 0 | 1 | 1 | 2013 | 0 | 3 | 3 | 2014 | 1 | 1 | 2 | 2015 | 0 | 2 | 2 | 2018 | 1 | 0 | 1 | 2021 | 1 | 1 | 2 | 2022 | 0 | 3 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Paclitaxel" by people in Profiles.
-
Duan L, Perez RE, Calhoun S, Maki CG. Inhibitors of Jumonji C domain-containing histone lysine demethylases overcome cisplatin and paclitaxel resistance in non-small cell lung cancer through APC/Cdh1-dependent degradation of CtIP and PAF15. Cancer Biol Ther. 2022 12 31; 23(1):65-75.
-
Modi S, Giri B, Gupta VK, Lavania S, Sethi V, Sharma NS, Pandey S, Vickers S, Dudeja V, Saluja AK. Minnelide synergizes with conventional chemotherapy by targeting both cancer and associated stroma components in pancreatic cancer. Cancer Lett. 2022 07 01; 537:215591.
-
Duan L, Perez RE, Calhoun S, Maki CG. RBL2/DREAM-mediated repression of the Aurora kinase A/B pathway determines therapy responsiveness and outcome in p53 WT NSCLC. Sci Rep. 2022 01 20; 12(1):1049.
-
Leslie KK, Filiaci VL, Mallen AR, Thiel KW, Devor EJ, Moxley K, Richardson D, Mutch D, Secord AA, Tewari KS, McDonald ME, Mathews C, Cosgrove C, Dewdney S, Casablanca Y, Jackson A, Rose PG, Zhou X, McHale M, Lankes H, Levine DA, Aghajanian C. Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study. Gynecol Oncol. 2021 04; 161(1):113-121.
-
Jelinek MJ, Foster NR, Zoroufy AJ, Schwartz GK, Munster PN, Seiwert TY, de Souza JA, Vokes EE. A phase I trial adding poly(ADP-ribose) polymerase inhibitor veliparib to induction carboplatin-paclitaxel in patients with head and neck squamous cell carcinoma: Alliance A091101. Oral Oncol. 2021 03; 114:105171.
-
Monk BJ, Kauderer JT, Moxley KM, Bonebrake AJ, Dewdney SB, Secord AA, Ueland FR, Johnston CM, Aghajanian C. A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2018 12; 151(3):422-427.
-
Dandekar VK, Young J, Kiel K, Bonomi P, Fidler MJ, Batus M, Sher DJ. Efficacy and Tolerability of Palliative Split-Course Thoracic Chemoradiotherapy for Symptomatic Non-Small Cell Lung Cancer. Am J Clin Oncol. 2015 Dec; 38(6):605-9.
-
Burton ER, Brady M, Homesley HD, Rose PG, Nakamura T, Kesterson JP, Rotmensch J, Tate Thigpen J, Van Le L. A phase II study of paclitaxel for the treatment of ovarian stromal tumors: An NRG Oncology/ Gynecologic Oncology Group Study. Gynecol Oncol. 2016 Jan; 140(1):48-52.
-
Spigel DR, Patel JD, Reynolds CH, Garon EB, Hermann RC, Govindan R, Olsen MR, Winfree KB, Chen J, Liu J, Guba SC, Socinski MA, Bonomi P. Quality of life analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Thorac Oncol. 2015 Feb; 10(2):353-9.
-
Reynolds CH, Patel JD, Garon EB, Olsen MR, Bonomi P, Govindan R, Pennella EJ, Liu J, Guba SC, Li S, Spigel DR, Hermann RC, Socinski MA, Obasaju CK. Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2015 May; 16(3):200-8.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|